Research ArticleResearchWorkflowMedication Safety

Chemotherapy-first rectal-cancer regimen improved pathologic response in a randomized trial

Journal of Gastrointestinal Cancer (PubMed)Jul 25, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

A randomized trial of 202 people with locally advanced rectal cancer found a higher pathologic complete response rate when chemotherapy preceded chemoradiotherapy and surgery than when chemoradiotherapy came first, while overall-survival results remained immature.

What NurseJet pulled from the source

Participants were assigned to chemotherapy-first total neoadjuvant therapy or conventional chemoradiotherapy followed by adjuvant chemotherapy and surgery. Pathologic complete response occurred in 55.4% versus 42.57%, respectively. Surgical outcomes were similar; thrombocytopenia was less frequent and dysuria more frequent with chemotherapy-first treatment. Overall survival did not differ significantly at the available follow-up.

Why this matters for nurses

Oncology nurses coordinate multi-stage treatment, monitor cumulative toxicity, reinforce symptom reporting, and help patients navigate transitions between chemotherapy, radiation, and surgery. A change in sequence shifts when those assessments, education needs, and handoffs occur even when the treatment components remain familiar.

Bedside takeaway

Chemotherapy-first treatment improved pathologic response, but the trial did not establish a survival advantage.

How This Applies in Practice

Use this when: Coordinating care for a patient receiving a multi-stage neoadjuvant regimen for locally advanced rectal cancer.

On your shift

Verify the treatment phase, next transition, and current monitoring plan during every oncology handoff.
Trend and escalate regimen-specific hematologic, urinary, gastrointestinal, and functional concerns through the oncology pathway.
When reinforcing education, distinguish the study's pathologic-response result from its still-immature survival evidence.

Keep in mind: This trial does not independently determine treatment selection or sequencing for an individual patient. Follow the oncology protocol, facility policy, and patient-specific provider orders.

Explain this for my unit

Key takeaways

The trial randomized 202 participants, with 101 assigned to each treatment sequence.
Pathologic complete response was 55.4% with chemotherapy-first treatment and 42.57% with the conventional sequence.
Sphincter preservation, resection margins, and surgical complications were similar between groups.
The survival analysis was exploratory and immature, so the response difference does not establish a long-term survival benefit.

Practice implications

Confirm the current phase and sequence at each handoff, reconcile treatment-specific monitoring and supportive-care plans, and promptly communicate hematologic, urinary, gastrointestinal, or other concerning symptoms. Present pathologic response and survival as separate outcomes during education.

Limitations & cautions

The trial addressed a resource-limited context and enrolled 202 participants. Overall survival was a secondary exploratory outcome and follow-up was not mature; larger studies with longer follow-up are needed before inferring a survival advantage or broad generalizability.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

Journal of Gastrointestinal Cancer (PubMed)

Journal of Gastrointestinal Cancer (PubMed). Prioritizing Chemotherapy in Total Neoadjuvant Therapy Improves pCR Rate in Locally Advanced Rectal Cancer in Countries with Limited Radiotherapy Access: A Randomized Controlled Trial.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42501213/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

EClinicalMedicine (PubMed)Jul 21, 2026Systematic ReviewPractice applicable

A JBI scoping review of 52 publications mapped nursing roles across precision cancer care and found uneven alignment between expanding competency expectations and available education, particularly for autonomous, interpretive, leadership, and governance responsibilities.

Oncology LeadershipAI summaryReview source

Systematic ReviewResearchPatient EducationWorkflowPractice applicableAI summary · original source linked below

The review identified five role areas: genomic risk assessment, genomic communication and shared decision-making, care-pathway coordination, interprofessional service integration, and governance or advanced practice. Sixty-five postgraduate or continuing-education programs were also identified, but most emphasized foundational knowledge rather than preparation for higher-autonomy roles. The authors proposed a three-level practice model rather than testing a clinical intervention.

Key takeaways

The review included 52 publications addressing precision-oncology nursing roles, competencies, or education.
Nursing contributions extended from genomic risk assessment and communication to navigation, service integration, and governance.
Most identified education emphasized foundational capabilities, with less explicit preparation for advanced interpretive and leadership roles.
The proposed three-level competency model is a framework and has not been validated as an education or patient-outcome intervention.

Why this matters on shift

Oncology nurses increasingly help patients navigate testing, results, treatment choices, and coordinated follow-up. The review highlights where role expectations may exceed formal preparation and gives educators and leaders a structure for matching education, supervision, and scope to the complexity of precision-cancer work.

Bedside takeaway

Precision-oncology nursing roles are broadening, while education for advanced interpretation, leadership, and governance remains uneven.

Nursing implications

Clarify which genomic conversations, assessments, and coordination tasks fall within the nurse's verified competency and local role. Use approved patient resources, route interpretive questions to qualified genetics or oncology clinicians, and document education and follow-up needs.

Limitations & cautions

This was a scoping review that mapped a heterogeneous literature and education landscape rather than evaluating effectiveness. The education search included generative-AI-assisted grey-literature methods, identified program availability may change, and the proposed competency levels require validation before they are used for credentialing or scope decisions.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

EClinicalMedicine (PubMed). Nursing roles, competencies, and education in precision oncology: a scoping review.

Explain this for my unit

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

The Oncologist (PubMed)Jul 20, 2026Research ArticlePractice applicable

Across 18 Central European oncology centers, 76 adults age 65 or older receiving sacituzumab govitecan had response, treatment-modification, and grade 3 or higher neutropenia outcomes comparable to younger patients, while age was not independently associated with survival after adjustment.

Oncology GeriatricsAI summaryReview source

Research ArticleResearchMedication SafetyPractice applicableAI summary · original source linked below

This retrospective multinational cohort included 303 adults with metastatic triple-negative breast cancer treated with sacituzumab govitecan, including 76 age 65 or older. Older patients had more comorbidities, more prior palliative treatment, and poorer performance status. Their unadjusted survival appeared longer, but age was not independently associated with overall or progression-free survival in multivariable models. Objective response, disease control, treatment modifications, and grade 3 or higher neutropenia were comparable by age. The authors attributed the unadjusted survival differences to baseline characteristics and selection rather than age itself.

Key takeaways

The real-world cohort included 303 patients treated at 18 oncology centers, with 76 patients age 65 or older.
Response, disease control, treatment modifications, and grade 3 or higher neutropenia were comparable between age groups.
Chronological age was not independently associated with overall or progression-free survival after adjustment.
The selected older group and retrospective design limit conclusions about frailer adults or causal treatment effects.

Why this matters on shift

Oncology nurses monitor treatment tolerance, laboratory trends, infection risk, and the practical effects of comorbidity and performance status. These data support individualized assessment rather than assuming that chronological age alone predicts poor tolerance or benefit.

Bedside takeaway

Selected older adults had comparable real-world outcomes and severe neutropenia, so tolerance assessment should extend beyond age alone.

Nursing implications

Review ordered blood counts and current symptoms before treatment, assess how comorbidities and functional status affect the care plan, and escalate fever, infection concerns, or suspected treatment toxicity promptly. Communicate trends and treatment interruptions so the oncology team can make patient-specific dosing and supportive-care decisions.

Limitations & cautions

This was a retrospective study of a selected treated population across Central European centers, and only 76 patients were age 65 or older. Age 65 does not capture frailty, selection into treatment may explain apparent similarities, and residual confounding remains. The abstract reports severe neutropenia but does not provide a complete age-stratified adverse-event profile.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

The Oncologist (PubMed). Clinical outcomes of sacituzumab govitecan in older patients with metastatic triple-negative breast cancer: a multinational real-world study.

Explain this for my unit

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (PubMed)Jul 18, 2026Research ArticlePractice applicable

In a single-center randomized trial of 210 adults aged 65 or older receiving chemotherapy for non-Hodgkin lymphoma, a multifactorial nursing program was associated with fewer falls over 12 weeks than standard oncology nursing (7.1% versus 19.8% among 194 participants who completed follow-up).

Oncology GeriatricsAI summaryReview source

Research ArticleResearchWorkflowQuality ImprovementPractice applicableAI summary · original source linked below

This prospective randomized trial assigned 210 older adults with newly diagnosed or relapsed non-Hodgkin lymphoma to individualized fall-risk assessment plus a multifactorial preventive nursing program or standard oncology nursing. Of 194 participants who completed 12 weeks of follow-up, fall incidence was 7.1% in the intervention group and 19.8% in the control group. The intervention group also had fewer severe injuries, better Timed Up and Go performance, higher chemotherapy completion, and higher quality-of-life scores. Because the study was conducted at one center and reports outcomes among completers, the results support structured fall-prevention assessment without establishing that one protocol will work in every oncology setting.

Key takeaways

The single-center randomized trial enrolled 210 adults aged 65 or older receiving chemotherapy for non-Hodgkin lymphoma.
Fall incidence among 194 follow-up completers was 7.1% with the preventive nursing program and 19.8% with standard care.
The intervention group also had better functional-mobility, chemotherapy-completion, and quality-of-life outcomes.
The 12-week, single-center design and completer analysis limit generalizability.

Why this matters on shift

Oncology nurses repeatedly assess mobility, neuropathy, anemia, treatment effects, and environmental risks that can change throughout chemotherapy. This trial directly tests a nursing-led approach for a high-risk older population.

Bedside takeaway

A multifactorial nursing program was associated with fewer falls in older adults receiving lymphoma chemotherapy, but the single-center protocol needs local review.

Nursing implications

Use the facility's oncology fall-risk process to reassess mobility and treatment-related risks across chemotherapy visits, then individualize prevention measures and document changes. Escalate new weakness, neuropathy, dizziness, falls, or injuries through the oncology team rather than adopting the study protocol without local review.

Limitations & cautions

The trial was conducted at one center, followed patients for 12 weeks, and reports results for 194 of 210 enrolled participants who completed follow-up. The abstract does not describe allocation concealment, blinding, or every component of the intervention, and the authors call for multicenter, longer-term validation.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (PubMed). A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial.

Explain this for my unit

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

Precision oncology review found nursing roles outpacing advanced genomic education

Older adults had comparable sacituzumab govitecan outcomes and severe toxicity in a selected real-world cohort

A tailored nursing program was associated with fewer falls during chemotherapy for older adults with lymphoma